A New, Automated Solution for Cell Isolation Upstream of Complement-Dependent Cytotoxicity Assay (CDC) Workflow

The HLA complement-dependent cytotoxicity (CDC) assay detects the binding of recipient antibodies to donor cells. This assay is performed as part of a pre-transplant immunology risk assessment to help determine the compatibility of donor-recipient pairs. In this recorded webinar, Petrina Fan describes the use of EasySep™ Serology CD3 and CD19 positive cell selection on RoboSep™-S for the CDC assay and provides information for validating these products for an optimized protocol. By the end of this webinar, the attendees will be familiar with the process involved in validating the CDC assay, the CDC assay protocol, and the automated isolation of T and B cells from whole blood. You can claim 0.15 ACHI continuing education credits (CECs) after viewing this webinar.
Publish Date: November 24, 2021

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.